<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047848</url>
  </required_header>
  <id_info>
    <org_study_id>CSIIT-C18</org_study_id>
    <nct_id>NCT05047848</nct_id>
  </id_info>
  <brief_title>Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer</brief_title>
  <official_title>Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaoning Tumor Hospital &amp; Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Open-label study of chidamide in combination with fulvestrant for the treatment of&#xD;
      postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer&#xD;
      who have received no or only one line of endocrine therapy for advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">September 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 26 months</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 26 months</time_frame>
    <description>PFS is defined as the time from the date of randomization to the date of the first documented progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 58 months</time_frame>
    <description>Time from date of randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to approximately 26 months</time_frame>
    <description>Clinical benefit rate (CBR), defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 26 months</time_frame>
    <description>Time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer as defined in RECIST 1.1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>chidamide + fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>chidamide 30mg orally，Biw</description>
    <arm_group_label>chidamide + fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1</description>
    <arm_group_label>chidamide + fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. women aged ≥ 18 years, histologically or cytologically confirmed HR positive (ER&#xD;
             expression ≥ 10%, PR positive or negative), HER2 negative breast cancer patients;&#xD;
&#xD;
          2. before enrollment for unresectable locally advanced or metastatic breast cancer, and&#xD;
             at least one measurable lesion or no measurable lesion and bone metastasis alone&#xD;
             patients;&#xD;
&#xD;
          3. For locally advanced or metastatic breast cancer, no previous endocrine therapy or&#xD;
             first-line endocrine therapy, and no previous use of CDK4/6 inhibitors. Specifically,&#xD;
             it includes the following conditions:&#xD;
&#xD;
             Cohort 1: (neo) recurrence &gt; 12 months after the end of adjuvant endocrine therapy,&#xD;
             and without any rescue therapy · newly diagnosed advanced breast cancer without any&#xD;
             rescue therapy Cohort 2: (neo) recurrence during or ≤ 12 months after the completion&#xD;
             of adjuvant endocrine therapy, and without any rescue therapy · recurrence &gt; 12 months&#xD;
             after the completion of adjuvant endocrine therapy, and progression by first-line&#xD;
             endocrine therapy · newly diagnosed advanced breast cancer and progression by&#xD;
             first-line endocrine rescue therapy&#xD;
&#xD;
          4. Cohort 1 without previous chemotherapy for advanced breast cancer; Cohort 2 with ≤ 1&#xD;
             previous chemotherapy for advanced breast cancer;&#xD;
&#xD;
          5. no brain metastasis or asymptomatic brain metastasis;&#xD;
&#xD;
          6. ECOG score 0-1;&#xD;
&#xD;
          7. Absolute neutrophil count ≥ 1.5 × 109/L, platelet ≥ 100 × 109/L, hemoglobin ≥ 90 g/L;&#xD;
&#xD;
          8. Expected survival time ≥ 3 months;&#xD;
&#xD;
          9. Voluntarily participate in this clinical trial, sign the written informed consent;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. no measurable lesions (except bone metastases alone), such as pleural or pericardial&#xD;
             exudates, ascites, etc.&#xD;
&#xD;
          2. Patients who have undergone major surgical procedures or significant trauma before&#xD;
             enrollment, or are expected to undergo major surgical treatment&#xD;
&#xD;
          3. Patients who have previously been treated with CDK4/6 inhibitors, fulvestrant or HDAC&#xD;
             inhibitors (including romidepsin, vorinostat, berlistat, parabrestat), but have&#xD;
             received 1 cycle (≤ 2 times, on d1, d15, respectively) of fulvestrant within 28 days&#xD;
             (before enrollment) are allowed&#xD;
&#xD;
          4. Known history of allergy to the drug components of this protocol&#xD;
&#xD;
          5. Meningeal metastasis before enrollment&#xD;
&#xD;
          6. Uncontrollable serosal effusion&#xD;
&#xD;
          7. Active infection [an active bacterial, viral, fungal, mycobacterial, parasitic or&#xD;
             other infection (excluding fungal infections of the nail bed) within 4 months prior to&#xD;
             Screening or any major infectious event requiring intravenous antibiotics, or targeted&#xD;
             antiviral therapy, or hospitalization], or persistent fever within 14 days prior to&#xD;
             Screening&#xD;
&#xD;
          8. a history of immunodeficiency, including HIV test positive, or suffering from other&#xD;
             acquired, congenital immunodeficiency diseases, or a history of organ transplantation;&#xD;
&#xD;
          9. according to the investigator's judgment, there are serious hazards to the patient's&#xD;
             safety, or affect the patient to complete the study of concomitant diseases (such as:&#xD;
             severe hypertension, diabetes, thyroid disease, active infection, etc.);&#xD;
&#xD;
         10. History of definite neurological or psychiatric disorders, including epilepsy or&#xD;
             dementia&#xD;
&#xD;
         11. Subjects who, in the opinion of the investigator, are not suitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sun Tao, Doctor</last_name>
    <phone>13940404526</phone>
    <email>lnzlrxnsy@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Liangning Tumor Hospital &amp;Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Tao, Doctor</last_name>
      <phone>13940404526</phone>
      <email>lnzlrxnsy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liaoning Tumor Hospital &amp; Institute</investigator_affiliation>
    <investigator_full_name>Tao Sun</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

